Expert Insights

John Leonard, MD, discusses recent therapeutic developments for aggressive DLBCL in the first- and second-line treatment settings, highlighting recent data around pelotuzumab vedotin and CAR-T therapies.

Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.

Robert Coleman, MD, discusses findings from a post hoc exploratory analysis of the ARIEL3 trial, which further evaluated the efficacy and safety of rucaparib maintenance in patients with platinum-sensitive, recurrent ovarian carcinoma who are...

Michael Gnant, MD, discusses findings from a study exploring long-term outcomes of adjuvant treatment with denosumab among patients with breast cancer receiving aromatase inhibitors.

Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.

Aleksandr Lazaryan, MD, PhD, MPH, discusses findings from a phase 2 study which explored the efficacy and safety of ofatumumab and prednisone as initial therapy for patients with chronic GVHD.

Debra Patt, MD, PhD, MBA, discusses practice changing results from the DESTINY-Breast04 trial, which showed a 50% reduction in the risk of disease progression or death with trastuzumab deruxtecan vs standard chemotherapy for patients with...

In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.

Robert Coleman, MD, discusses findings from the phase 3 ATHENA-MONO trial which compared rucaparib vs placebo for maintenance therapy in patients with advanced-stage ovarian cancer.

In part 1 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses the current emerging therapies for platinum-resistant ovarian malignancies.